Nuvo Pharmaceuticals Inc (TSE:NRI) was downgraded by equities researchers at Bloom Burton from a “buy” rating to an “accumulate” rating in a research note issued on Friday.

Shares of Nuvo Pharmaceuticals (NRI) traded down C$0.09 during trading hours on Friday, reaching C$4.00. 21,329 shares of the company traded hands, compared to its average volume of 7,562. Nuvo Pharmaceuticals has a 52-week low of C$3.76 and a 52-week high of C$6.43.

TRADEMARK VIOLATION NOTICE: This article was first posted by American Banking News and is the property of of American Banking News. If you are accessing this article on another site, it was illegally copied and reposted in violation of United States and international copyright legislation. The legal version of this article can be read at https://www.americanbankingnews.com/2017/11/04/nuvo-pharmaceuticals-inc-nri-lowered-to-accumulate-at-bloom-burton.html.

Nuvo Pharmaceuticals Company Profile

Nuvo Pharmaceuticals Inc, formerly Nuvo Research Inc, is a Canada-based healthcare company. The Company offers a range of commercial products, including Pennsaid 2%, Pennsaid and the heated lidocaine/tetracaine (HLT) patch. The Company’s Pennsaid 2% is a non-steroidal anti-inflammatory drug (NSAID) containing 2% diclofenac sodium.

Receive News & Ratings for Nuvo Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvo Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.